<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380416</url>
  </required_header>
  <id_info>
    <org_study_id>16/17</org_study_id>
    <nct_id>NCT03380416</nct_id>
  </id_info>
  <brief_title>Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients</brief_title>
  <acronym>MEDEA</acronym>
  <official_title>Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with type 2 diabetes and non-alcoholic fatty liver disease will be enrolled.

      According to a parallel design, the participants will be randomized to a Portfolio diet or a
      monounsaturated fatty acid (MUFA)-rich diet (used as control) for 8 weeks.

      At the beginning and at the end of the trial, the participants will undergo a MRI
      spectroscopy to evaluate fatty liver content. Moreover, the participants will undergo a test
      meal resembling the nutritional composition of the assigned diet to evaluate fasting and
      postprandial metabolic response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fat content</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>MRI spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver functionality</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>Liver enzymes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>Flow-mediated dilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>Transient Elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>glucose homeostasis (glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>bioimpedance analyses (BIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipids</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subclinical inflammation</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>elisa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>urinary isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>glucose homeostasis (HbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>Change from Baseline after 8 weeks</time_frame>
    <description>glucose homeostasis (Insulin)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Diabetes Type 2</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Portfolio Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUFA Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Portfolio Diet</intervention_name>
    <description>Medium-term (8 weeks ) nutritional intervention</description>
    <arm_group_label>Portfolio Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MUFA Diet</intervention_name>
    <description>Medium-term (8 weeks ) nutritional intervention used as control</description>
    <arm_group_label>MUFA Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  non-alcoholic fatty liver disease (evaluated by US)

          -  HbA1c &lt;7.5%

          -  LDL cholesterol &lt;130 mg/dl

        Exclusion Criteria:

          -  hypoglycemic therapy with sodium-glucose cotransporter (SGLT-2), pioglitazone and
             glucagon-like peptide (GLP-1) analogues

          -  severe liver and kidney failure

          -  recent cardiovascular events (prior 6 months)

          -  any other acute/chronic disease (anemia, cancer, BPCO)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Medicine and Surgery</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela A Rivellese</last_name>
      <phone>+39 0817462154</phone>
      <email>rivelles@unina.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>rivellese angela</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

